Information Provided By:
Fly News Breaks for July 20, 2016
SRPT
Jul 20, 2016 | 07:52 EDT
Janney Capital analyst Debjit Chattopadhyay said that if Sarepta's biopsy data was "outright negative," the company could have used the 8K associated with its earlier-than-usual second quarter report last night to update investors. Given the company's silence, Chattopadhyay sees it as "likely" that eteplirsen generated de novo dystrophin in the majority of patients. If that is the case, it still remains unknown if the results were statistically-significant compared to baseline and if they met the agency's expectations, the analyst added. If the de novo dystrophin was significantly higher than baseline, accelerated approval is the logical outcome, said Chattopadhyay, who keeps a Neutral rating and $25 fair value estimate on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT